Globus Medical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Globus Medical and other ETFs, options, and stocks.

About GMED

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. It engages in developing products that promote healing in patients with musculoskeletal disorders. 

CEO
Keith W. Pfeil
CEOKeith W. Pfeil
Employees
6,000
Employees6,000
Headquarters
Audubon, Pennsylvania
HeadquartersAudubon, Pennsylvania
Founded
2003
Founded2003
Employees
6,000
Employees6,000

GMED Key Statistics

Market cap
12.85B
Market cap12.85B
Price-Earnings ratio
24.64
Price-Earnings ratio24.64
Dividend yield
Dividend yield
Average volume
1.32M
Average volume1.32M
High today
$96.00
High today$96.00
Low today
$92.79
Low today$92.79
Open price
$94.73
Open price$94.73
Volume
1.17M
Volume1.17M
52 Week high
$101.40
52 Week high$101.40
52 Week low
$51.79
52 Week low$51.79

Stock Snapshot

The current Globus Medical(GMED) stock price is $95.46, with a market capitalization of 12.85B. The stock trades at a price-to-earnings (P/E) ratio of 24.64.

On 2026-02-27, Globus Medical(GMED) stock traded between a low of $92.79 and a high of $96.00. Shares are currently priced at $95.46, which is +2.9% above the low and -0.6% below the high.

Globus Medical(GMED) shares are trading with a volume of 1.17M, against a daily average of 1.32M.

In the last year, Globus Medical(GMED) shares hit a 52-week high of $101.40 and a 52-week low of $51.79.

In the last year, Globus Medical(GMED) shares hit a 52-week high of $101.40 and a 52-week low of $51.79.

GMED News

TipRanks 2d
Globus Medical Earnings Call Shows Profitable Growth

Globus Medical ((GMED)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 50% Off TipRanks Premium Unlock hedge fund-level data...

Simply Wall St 2d
Is It Too Late To Consider Globus Medical After Recent Share Price Strength?

If you are wondering whether Globus Medical's current share price reflects its true worth, you are not alone. This article focuses squarely on what the numbers...

Is It Too Late To Consider Globus Medical After Recent Share Price Strength?
TipRanks 2d
Globus Medical: Strengthening U.S. Spine Momentum and Innovation-Driven Double-Digit Growth Supports Buy Rating and Upside Valuation

TD Cowen analyst Mathew Blackman maintained a Buy rating on Globus Medical today and set a price target of $112.00. Mathew Blackman has given his Buy rating du...

Analyst ratings

65%

of 17 ratings
Buy
64.7%
Hold
29.4%
Sell
5.9%

More GMED News

TipRanks 2d
Globus Medical price target raised to $123 from $118 at Barclays

Barclays analyst Matt Miksic raised the firm’s price target on Globus Medical (GMED) to $123 from $118 and keeps an Overweight rating on the shares following th...

Nasdaq 3d
Globus Medical, Inc. Reports Advance In Q4 Profit

(RTTNews) - Globus Medical, Inc. (GMED) revealed earnings for its fourth quarter that Increases, from last year The company's bottom line came in at $140.59 mi...

Globus Medical, Inc. Reports Advance In Q4 Profit
TipRanks 3d
Globus Medical reports Q4 EPS $1.28, consensus 96c

Reports Q4 revenue $826.4M, consensus $803.29M. “Momentum built throughout 2025 accelerated in the fourth quarter, capping off a strong finish to the year with...

People also own

Based on the portfolios of people who own GMED. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.